Listen to this article

Becton, Dickinson and Co. plans to invest more than $110 million to expand a prefilled flush syringe manufacturing facility in Nebraska. According to BD, the plan aims to better meet growing demand for biologic drugs.

The Franklin Lakes-based medical technology company announced the investment in a Jan. 13 press release. The company said the capital will go toward establishing production of its BD Neopak Glass Prefillable Syringes at the 76-year-old site.

Along with upgrading product lines and making capacity improvements, BD will hire about 120 new employees, the company said.

The Purpose-built BD Neopak Glass Prefillable Syringe platform supports a wide range of formulation requirements. It is designed with autoinjectors to allow flexible, patient-centric drug delivery in both clinical and at-home settings.

Patrick Jeukenne, worldwide president of pharmaceutical services at BD, said, “As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency.”

“This investment in Nebraska, advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions,” he said.

Domestic investments

It comes about five months after BD revealed plans to spend more than $35 million to increase prefilled flush syringe manufacturing in Columbus and create 50 new jobs.

The newly announced commitment also builds on BD’s broader efforts to strengthen U.S. health care infrastructure and ensure long-term supply resilience.

In January 2025, the company pledged to put $2.5 billion into growing domestic manufacturing over the next five years.

That includes more than $40 million in investments across its U.S. manufacturing network to expand capacity for syringes, needles and IV catheters — products essential to everyday clinical care.

Across the U.S., BD has more than 30 manufacturing and distribution facilities.

The investments come as BD continues to slim down in an effort to focus on its core business. After spinning off its diabetes care unit four years ago, BD plans to divest its diagnostic and biosciences divisions and continue as a pure-play medtech company.

Under a $17.5 billion deal announced in July 2025, BD plans to sell its units to Waters Corp. The transaction is expected to close around the end of the first quarter of 2026.